Theravance Biopharma Stock Price, News & Analysis (NASDAQ:TBPH)

$27.04 -1.17 (-4.15 %)
(As of 02/23/2018 09:55 AM ET)
Previous Close$27.04
Today's Range$27.00 - $28.67
52-Week Range$22.90 - $43.44
Volume179,600 shs
Average Volume220,196 shs
Market Capitalization$1.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.88

About Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma logoTheravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TBPH
CUSIPN/A
Phone650-808-6000

Debt

Debt-to-Equity Ratio1.21%
Current Ratio7.53%
Quick Ratio7.21%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$48.65 million
Price / Sales30.07
Cash FlowN/A
Price / CashN/A
Book Value$6.74 per share
Price / Book4.01

Profitability

Trailing EPS($5.17)
Net Income$-190,660,000.00
Net Margins-1,604.87%
Return on Equity-99.43%
Return on Assets-47.10%

Miscellaneous

Employees316
Outstanding Shares54,100,000

Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma Inc (NASDAQ:TBPH) announced its quarterly earnings results on Monday, August, 8th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.05) by $0.01. The biopharmaceutical company earned $5.47 million during the quarter, compared to analysts' expectations of $6.19 million. Theravance Biopharma had a negative net margin of 1,604.87% and a negative return on equity of 99.43%. View Theravance Biopharma's Earnings History.

Where is Theravance Biopharma's stock going? Where will Theravance Biopharma's stock price be in 2018?

6 brokers have issued 12-month price targets for Theravance Biopharma's stock. Their forecasts range from $22.00 to $55.00. On average, they expect Theravance Biopharma's share price to reach $42.83 in the next twelve months. View Analyst Ratings for Theravance Biopharma.

What are Wall Street analysts saying about Theravance Biopharma stock?

Here are some recent quotes from research analysts about Theravance Biopharma stock:

  • 1. Needham & Company LLC analysts commented, "We recently hosted a series of mtgs w/ investors and Theravance mgmt. TD-1473 JAK inhibitor and GSK respiratory programs were typical starting points for discussion. Mgmt plans to initiate TD-1473 Phase 2b induction/ maintenance trial in Ulcerative Colitis in mid-2018. Initial data from TD-1473 Phase 1b trial in this indication are consistent w/activity in our opinion. Number of doses and patients in Phase 2b trial will depend on data from additional Phase 1b cohorts, which mgmt has not yet seen. GSK launched Trelegy for COPD last month (5.5-8.5% royalty to Theravance). Significant time also spent on TD-9855 and velusetrag, both of which appear on path for Phase 3 initiation in 2018. Reiterate BUY. We believe stock is undervalued ($1.3B EV), given continued maturation of diversified pipeline." (12/5/2017)
  • 2. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) Revefenacin NDA filing anticipated in 4Q17, potential regulatory approval in the U.S. for COPD in ’18, Phase 3b PIFR study, designed to support commercialization, expected to complete in 1Q18.; 2) Trelegy Ellipta, commercial launch expected mid-November ’17, economic interest related to Trelegy Ellipta entitles TBPH to upward tiering royalty of 5.5-8.5% on worldwide net sales; potential regulatory approval in the EU for COPD in late ’17, Phase 3 CAPTAIN study in asthma patients expected to complete in ’18; 3) TD-1473 data from the remaining cohorts of the Phase 1b study in patients with ulcerative colitis in ’18, targeting initiation of large, multi-dose induction and maintenance study in ’18; 4) TD-9855, data from the Phase 2a study in patients with nOH in 1H18; 5) Vibativ, Observational Use Registry (TOUR) data to be published in ’18, data from the Phase 3 registrational bacteremia study in ’18 or ’19; and, 4) Cash and equivalents totaled $434.4MM as of 9/30/17." (11/7/2017)
  • 3. According to Zacks Investment Research, "Theravance has only one marketed product in its portfolio, Vibativ. Though Vibativ continues to perform well, the company’s sole dependence on the drug for growth is concerning. Moreover, its pipeline programs targeting the therapeutic areas are highly competitive which could affect the company’s operating results. Also, any agreement termination might be a huge setback for the company, as had been the case in the past. However, we are positive on Theravance’s efforts to expand the Vibativ’s label, which, if approved for additional indications, would be commercially significant. Further, Theravance’s collaboration agreement with Mylan for revefenacin, is a big positive. Its shares have outperformed the industry so far this year." (10/10/2017)

Who are some of Theravance Biopharma's key competitors?

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the folowing people:

  • Rick E. Winningham, Chairman of the Board, Chief Executive Officer (Age 57)
  • Renee D. Gala, Senior Vice President, Chief Financial Officer, Treasurer (Age 45)
  • Bradford J. Shafer Esq. J.D., Executive Vice President, General Counsel, Secretary (Age 57)
  • Brett K. Haumann M.D., Senior Vice President - Clinical Development and Chief Medical Officer (Age 47)
  • Sharathchandra S. Hegde, Senior Vice President, Research (Age 53)
  • Frank Pasqualone, Senior Vice President and Chief Commercial Operations Officer (Age 61)
  • Kenneth R. Pitzer, Senior Vice President - Product Strategy and Commercial Planning (Age 53)
  • Shehnaaz Suliman M.D., Senior Vice President - Corporate Development and Strategy
  • Philip D. Worboys Ph.D., Senior Vice President, Translational Science (Age 47)
  • William D. Young, Lead Independent Director (Age 72)

Who owns Theravance Biopharma stock?

Theravance Biopharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Woodford Investment Management Ltd (19.87%), BlackRock Inc. (6.92%), First Manhattan Co. (2.69%), Schwab Charles Investment Management Inc. (0.37%), Goldman Sachs Group Inc. (0.37%) and Senzar Asset Management LLC (0.32%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Frank Pasqualone, Henrietta Fore, Plc Glaxosmithkline and Rick E Winningham. View Institutional Ownership Trends for Theravance Biopharma.

Who sold Theravance Biopharma stock? Who is selling Theravance Biopharma stock?

Theravance Biopharma's stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., BlackRock Inc., Goldman Sachs Group Inc., Senzar Asset Management LLC, Rhumbline Advisers, TIAA CREF Investment Management LLC and UBS Asset Management Americas Inc.. Company insiders that have sold Theravance Biopharma company stock in the last year include Bradford J Shafer and Brett K Haumann. View Insider Buying and Selling for Theravance Biopharma.

Who bought Theravance Biopharma stock? Who is buying Theravance Biopharma stock?

Theravance Biopharma's stock was bought by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Woodford Investment Management Ltd, Virtus Fund Advisers LLC, Wells Fargo & Company MN, Millennium Management LLC, Teacher Retirement System of Texas, Landscape Capital Management L.L.C. and Schwab Charles Investment Management Inc.. Company insiders that have bought Theravance Biopharma stock in the last two years include Frank Pasqualone, Henrietta Fore, Plc Glaxosmithkline and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.

How do I buy Theravance Biopharma stock?

Shares of Theravance Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of Theravance Biopharma stock can currently be purchased for approximately $27.04.

How big of a company is Theravance Biopharma?

Theravance Biopharma has a market capitalization of $1.53 billion and generates $48.65 million in revenue each year. The biopharmaceutical company earns $-190,660,000.00 in net income (profit) each year or ($5.17) on an earnings per share basis. Theravance Biopharma employs 316 workers across the globe.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]


MarketBeat Community Rating for Theravance Biopharma (TBPH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  302
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Theravance Biopharma (NASDAQ:TBPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.71
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $42.83$42.67$42.67$42.57
Price Target Upside: 53.63% upside59.20% upside51.35% upside57.50% upside

Theravance Biopharma (NASDAQ:TBPH) Consensus Price Target History

Price Target History for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018Leerink SwannBoost Price TargetOutperform$45.00 -> $48.00MediumView Rating Details
12/5/2017Needham & Company LLCReiterated RatingBuyHighView Rating Details
11/7/2017Cantor FitzgeraldReiterated RatingBuy$55.00N/AView Rating Details
11/1/2017Robert W. BairdReiterated RatingSell$22.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$45.00MediumView Rating Details
3/22/2017Piper Jaffray CompaniesReiterated RatingOverweight$42.00MediumView Rating Details
9/19/2016GuggenheimReiterated RatingPositive$40.00N/AView Rating Details
8/3/2016Bank of AmericaDowngradeNeutral -> UnderperformN/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Theravance Biopharma (NASDAQ:TBPH) Earnings History and Estimates Chart

Earnings by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ TBPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($1.22)($1.27)$3.60 million$4.28 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.13)($1.27)$4.06 million$3.51 millionViewN/AView Earnings Details
5/9/20173/31/2017($1.14)($1.27)$5.07 million$3.09 millionViewListenView Earnings Details
2/27/2017Q416($1.05)($1.36)$5.00 million$5.69 millionViewListenView Earnings Details
11/8/2016Q3 2016($0.95)($0.73)$16.41 million$19.08 millionViewN/AView Earnings Details
8/8/2016Q216($1.05)($1.06)$6.19 million$5.47 millionViewN/AView Earnings Details
5/9/2016Q116($0.96)($1.10)$18.69 million$18.40 millionViewN/AView Earnings Details
3/9/2016Q415($1.62)($1.23)($280,000.00) million$3.90 millionViewN/AView Earnings Details
11/9/2015Q315($1.44)($1.40)$4.24 million$10.70 millionViewN/AView Earnings Details
8/10/2015Q215($1.51)($1.42)$4.25 million$7.10 millionViewListenView Earnings Details
5/7/2015Q1 2015($1.57)($1.29)$7.55 million$20.40 millionViewN/AView Earnings Details
3/10/2015Q414($1.70)($2.02)$2.01 million$1.30 millionViewN/AView Earnings Details
11/6/2014Q3 14($1.85)($1.72)$1.08 million$6.34 millionViewN/AView Earnings Details
8/13/2014($0.56)($1.83)$1.01 million$2.97 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Theravance Biopharma (NASDAQ:TBPH) Earnings Estimates

2018 EPS Consensus Estimate: ($3.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.71$0.71$0.71
Q2 20181($1.24)($1.24)($1.24)
Q3 20181($1.39)($1.39)($1.39)
Q4 20181($1.15)($1.15)($1.15)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Theravance Biopharma (NASDAQ:TBPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Theravance Biopharma (NASDAQ TBPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 85.75%
Insider Trades by Quarter for Theravance Biopharma (NASDAQ:TBPH)
Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ TBPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/6/2017Bradford J ShaferEVPSell14,670$30.77$451,395.90134,327View SEC Filing  
8/21/2017Frank PasqualoneSVPBuy4,000$26.34$105,360.00213,180View SEC Filing  
8/11/2017Henrietta ForeDirectorBuy6,000$23.99$143,940.0024,000View SEC Filing  
8/11/2017Rick E WinninghamCEOBuy10,000$24.50$245,000.00866,377View SEC Filing  
3/7/2017Brett K HaumannSVPSell424$30.80$13,059.20163,895View SEC Filing  
3/6/2017Brett K HaumannSVPSell13,576$31.52$427,915.52163,895View SEC Filing  
8/25/2016Brett K HaumannSVPSell4,491$27.99$125,703.09188,293View SEC Filing  
8/22/2016Bradford J ShaferEVPSell49,122$27.46$1,348,890.12241,686View SEC Filing  
8/19/2016Brett K HaumannSVPSell9,509$27.97$265,966.73197,391View SEC Filing  
3/14/2016Plc GlaxosmithklineMajor ShareholderBuy1,301,015$23,028,000.00$29,959,773,420,000.00View SEC Filing  
10/7/2015Plc GlaxosmithklineMajor ShareholderBuy44,574$607,544.00$27,080,666,256.00View SEC Filing  
8/18/2015Burton G MalkielDirectorBuy10,000$12.92$129,200.00View SEC Filing  
8/18/2015Junning LeeVPBuy9,000$12.90$116,100.00View SEC Filing  
8/17/2015Renee D GalaCFOBuy10,000$12.18$121,800.00View SEC Filing  
8/17/2015Rick E WinninghamCEOBuy80,000$11.86$948,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Theravance Biopharma (NASDAQ TBPH) News Headlines

Source:
DateHeadline
Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial ...Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial ...
www.prnewswire.com - February 21 at 9:35 AM
Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
finance.yahoo.com - February 20 at 9:07 AM
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to ...Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to ...
www.prnewswire.com - February 16 at 9:09 AM
Theravance Biopharma (TBPH) Highlights Submission of IMPACT Data to EMA to Support Expanded Label for Trelegy ElliptaTheravance Biopharma (TBPH) Highlights Submission of IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta
www.streetinsider.com - February 16 at 9:09 AM
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy ElliptaTheravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta
finance.yahoo.com - February 15 at 8:46 AM
Theravance Biopharma Inc to Post FY2017 Earnings of ($4.96) Per Share, Leerink Swann Forecasts (TBPH)Theravance Biopharma Inc to Post FY2017 Earnings of ($4.96) Per Share, Leerink Swann Forecasts (TBPH)
www.americanbankingnews.com - February 12 at 1:08 AM
Theravance Biopharma (TBPH) Lifted to "Sell" at BidaskClubTheravance Biopharma (TBPH) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - February 11 at 6:54 AM
Wired News – Theravance Biopharma Signs Global Collaboration Agreement with Janssen for TD-1473Wired News – Theravance Biopharma Signs Global Collaboration Agreement with Janssen for TD-1473
finance.yahoo.com - February 9 at 9:11 AM
Theravance Biopharma Inc (TBPH) Expected to Announce Quarterly Sales of $3.71 MillionTheravance Biopharma Inc (TBPH) Expected to Announce Quarterly Sales of $3.71 Million
www.americanbankingnews.com - February 9 at 3:48 AM
Theravance Biopharma Inc (TBPH) Given Consensus Rating of "Hold" by AnalystsTheravance Biopharma Inc (TBPH) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 9 at 1:48 AM
Commit To Purchase Theravance Biopharma At $22.50, Earn 9.7% Annualized Using OptionsCommit To Purchase Theravance Biopharma At $22.50, Earn 9.7% Annualized Using Options
www.nasdaq.com - February 8 at 4:25 PM
Leerink Swann Boosts Theravance Biopharma (TBPH) Price Target to $48.00Leerink Swann Boosts Theravance Biopharma (TBPH) Price Target to $48.00
www.americanbankingnews.com - February 8 at 10:34 AM
Theravance Biopharma Inc (TBPH) Expected to Announce Earnings of -$1.15 Per ShareTheravance Biopharma Inc (TBPH) Expected to Announce Earnings of -$1.15 Per Share
www.americanbankingnews.com - February 7 at 11:16 AM
Theravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal DiseasesTheravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal Diseases
finance.yahoo.com - February 7 at 9:12 AM
Theravance Biopharma (TBPH) Cut to Strong Sell at BidaskClubTheravance Biopharma (TBPH) Cut to Strong Sell at BidaskClub
www.americanbankingnews.com - February 3 at 10:12 AM
 Analysts Expect Theravance Biopharma Inc (TBPH) Will Post Quarterly Sales of $3.71 Million Analysts Expect Theravance Biopharma Inc (TBPH) Will Post Quarterly Sales of $3.71 Million
www.americanbankingnews.com - January 23 at 8:58 AM
-$1.15 EPS Expected for Theravance Biopharma Inc (TBPH) This Quarter-$1.15 EPS Expected for Theravance Biopharma Inc (TBPH) This Quarter
www.americanbankingnews.com - January 21 at 1:08 PM
Theravance Biopharma (TBPH) Upgraded by BidaskClub to "Sell"Theravance Biopharma (TBPH) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - January 20 at 9:00 AM
Theravance Biopharma Inc (TBPH) Given Average Rating of "Hold" by BrokeragesTheravance Biopharma Inc (TBPH) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 15 at 1:38 AM
Zacks: Brokerages Anticipate Theravance Biopharma Inc (TBPH) to Post -$1.15 Earnings Per ShareZacks: Brokerages Anticipate Theravance Biopharma Inc (TBPH) to Post -$1.15 Earnings Per Share
www.americanbankingnews.com - January 4 at 5:32 PM
Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : January 1, 2018Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : January 1, 2018
finance.yahoo.com - January 1 at 10:56 AM
Theravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Theravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 10:56 AM
Contrasting Theravance Biopharma (TBPH) & Sophiris Bio (SPHS)Contrasting Theravance Biopharma (TBPH) & Sophiris Bio (SPHS)
www.americanbankingnews.com - January 1 at 7:38 AM
Comparing Marinus Pharmaceuticals (MRNS) & Theravance Biopharma (TBPH)Comparing Marinus Pharmaceuticals (MRNS) & Theravance Biopharma (TBPH)
www.americanbankingnews.com - December 31 at 10:06 PM
Zacks: Analysts Anticipate Theravance Biopharma Inc (TBPH) Will Announce Quarterly Sales of $3.71 MillionZacks: Analysts Anticipate Theravance Biopharma Inc (TBPH) Will Announce Quarterly Sales of $3.71 Million
www.americanbankingnews.com - December 21 at 2:02 PM
Theravance Biopharma Inc (TBPH) Given Average Rating of "Hold" by AnalystsTheravance Biopharma Inc (TBPH) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - December 21 at 2:04 AM
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy ElliptaTheravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta
finance.yahoo.com - December 7 at 3:55 PM
Theravance Biopharma Enters Oversold Territory (TBPH)Theravance Biopharma Enters Oversold Territory (TBPH)
www.nasdaq.com - December 7 at 11:44 AM
Needham & Company LLC Reaffirms Buy Rating for Theravance Biopharma (TBPH)Needham & Company LLC Reaffirms Buy Rating for Theravance Biopharma (TBPH)
www.americanbankingnews.com - December 5 at 8:48 PM
Financial Comparison: Johnson & Johnson (JNJ) vs. Theravance Biopharma (TBPH)Financial Comparison: Johnson & Johnson (JNJ) vs. Theravance Biopharma (TBPH)
www.americanbankingnews.com - December 4 at 3:18 PM
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to ...Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to ...
www.prnewswire.com - November 30 at 11:58 AM
Theravance Biopharma, Inc. (TBPH) Cut to Sell at ValuEngineTheravance Biopharma, Inc. (TBPH) Cut to Sell at ValuEngine
www.americanbankingnews.com - November 26 at 8:48 AM
Critical Analysis: Theravance Biopharma (TBPH) vs. Its RivalsCritical Analysis: Theravance Biopharma (TBPH) vs. Its Rivals
www.americanbankingnews.com - November 26 at 7:12 AM
Theravance Biopharma, Inc. (TBPH) Given Average Recommendation of "Hold" by BrokeragesTheravance Biopharma, Inc. (TBPH) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 26 at 1:38 AM
Theravance Biopharma to Present at Two Upcoming Investor ConferencesTheravance Biopharma to Present at Two Upcoming Investor Conferences
finance.yahoo.com - November 21 at 11:32 AM
Theravance Biopharma to Present at Two Upcoming Investor ConferencesTheravance Biopharma to Present at Two Upcoming Investor Conferences
finance.yahoo.com - November 21 at 11:32 AM
Theravance Biopharma (TBPH) Reports European Marketing Authorization for ...Theravance Biopharma (TBPH) Reports European Marketing Authorization for ...
www.streetinsider.com - November 18 at 9:11 AM
3 Things In Biotech You Should Learn Today: November 14, 20173 Things In Biotech You Should Learn Today: November 14, 2017
seekingalpha.com - November 15 at 1:59 PM
$3.72 Million in Sales Expected for Theravance Biopharma, Inc. (TBPH) This Quarter$3.72 Million in Sales Expected for Theravance Biopharma, Inc. (TBPH) This Quarter
www.americanbankingnews.com - November 14 at 6:04 AM
-$1.15 EPS Expected for Theravance Biopharma, Inc. (TBPH) This Quarter-$1.15 EPS Expected for Theravance Biopharma, Inc. (TBPH) This Quarter
www.americanbankingnews.com - November 12 at 1:24 PM
Theravance Biopharma, Inc. Forecasted to Earn FY2017 Earnings of ($4.95) Per Share (TBPH)Theravance Biopharma, Inc. Forecasted to Earn FY2017 Earnings of ($4.95) Per Share (TBPH)
www.americanbankingnews.com - November 10 at 12:54 PM
Theravance Bio reports 3Q lossTheravance Bio reports 3Q loss
finance.yahoo.com - November 9 at 2:29 PM
Edited Transcript of TBPH earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of TBPH earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 9 at 2:29 PM
Theravance Biopharma, Inc. (TBPH) Rating Reiterated by Cantor FitzgeraldTheravance Biopharma, Inc. (TBPH) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - November 7 at 7:48 PM
Head to Head Analysis: Theravance Biopharma (TBPH) vs. Aegerion Pharmaceuticals (AEGR)Head to Head Analysis: Theravance Biopharma (TBPH) vs. Aegerion Pharmaceuticals (AEGR)
www.americanbankingnews.com - November 3 at 11:20 PM
Reviewing Theravance Biopharma (TBPH) and Its CompetitorsReviewing Theravance Biopharma (TBPH) and Its Competitors
www.americanbankingnews.com - November 2 at 7:22 PM
Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR ...Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR ...
www.prnewswire.com - November 1 at 9:38 AM
Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR ...Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR ...
www.prnewswire.com - November 1 at 9:38 AM
Theravance Biopharma (TBPH) Announces Positive New VIBATIV (Telavancin) Data from TOUR Observational Patient RegistryTheravance Biopharma (TBPH) Announces Positive New VIBATIV (Telavancin) Data from TOUR Observational Patient Registry
www.streetinsider.com - November 1 at 9:38 AM
Theravance Biopharma (TBPH) Announces Positive New VIBATIV (Telavancin) Data from TOUR Observational Patient RegistryTheravance Biopharma (TBPH) Announces Positive New VIBATIV (Telavancin) Data from TOUR Observational Patient Registry
www.streetinsider.com - November 1 at 9:38 AM

SEC Filings

Theravance Biopharma (NASDAQ:TBPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Theravance Biopharma (NASDAQ:TBPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Theravance Biopharma (NASDAQ TBPH) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.